initial public offerings (IPOs) trading on American exchanges

Monday, August 25, 2014

Amphastar Pharmaceuticals (AMPH) began trading on the NASDAQ on 25 June 2014


Amphastar Pharmaceuticals, Inc. is a specialty and generic pharmaceutical company. The Company focuses primarily on developing, manufacturing, marketing and selling technically challenging generic and injectable and inhalation products. The Company’s generic product candidates at various development stages that leverage its various technical capabilities, including injectable technologies, including various delivery methods and sizes of pre-filled syringes, vials in solution, suspension and lyophilized forms; inhalation technologies, including metered dose inhalers (MDIs) and metered dose inhalers (DPIs); and analytical technologies. As of May 20, 2014, the Company manufactures and sells 15 products in the United States and is developing a portfolio of 13 generic and seven injectable and inhalation product candidates. In addition to its marketed products, it has a pipeline of 20 generic and product candidates in various stages of development which target a variety of indications.


11570 6th St
United States

Key stats and ratios

Q2 (Jun '14)2013
Net profit margin-2.41%5.16%
Operating margin-2.39%7.61%
EBITD margin-13.36%
Return on average assets-1.28%3.55%
Return on average equity-1.76%4.89%

No comments:

Post a Comment